Cell Source, Inc. is an immunotherapy and regenerative medicine company whose primary breakthrough is the regulation of immune tolerance. In preclinical studies CLCS therapies have demonstrated the ability to directly address a number of severe medical conditions such as blood cancers such as non-Hodgkins lymphoma, multiple myeloma, and chronic lymphocytic leukemia.  For more information, visit the company’s website at www.cell-source.com.